Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) IgG, Blood Spot
- GTR Test IDHelpEach Test is a specific, orderable test from a particular laboratory, and is assigned a unique GTR accession number. The format is GTR00000001.1, with a leading prefix 'GTR' followed by 8 digits, a period, then 1 or more digits representing the version. When a laboratory updates a registered test, a new version number is assigned.: GTR000592503.2
- Last updated: 2021-07-14
- Annual Review past due read more
- Test version history
Clinical microbial testHelpIn the U.S., clinical tests must be performed under CLIA certification. When a lab uses the same methods for a test in both clinical and research settings, the test appears as two separate GTR records. for COVID-19
Offered by Clinical Microbiology
Overview
Test name
HelpThe name the laboratory assigns the test. Used as the default title of the page specific to the test.Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) IgG, Blood Spot (SARS-CoV-2 IgG, Bld Spot)
This is a clinical microbial test intended for HelpPurposes or indications for the test. Lab-provided.: Screening
Click Indication tab for more information.
CPT Code 86769. Contact Customer Service (https://www.mayocliniclabs.com/customer-service/contacts.html)
Order URL HelpLink to the laboratory webpage with information about how to order this test. Please note that clicking on this link will open a new tab in your internet browser.: https://www.mayocliniclabs.com/order-tests/account-setup.html
Specimen source
Sample requirements
For details on sample collection, see https://www.mayocliniclabs.com/test-catalog/Specimen/609799Turnaround time
48 hoursMethodology
HelpThe assay's major method category (biochemical, cytogenetic or molecular genetics); method category (i.e. enzyme assay, chromosome breakage studies, targeted mutation analysis); methodology (i.e. the name of the method used) and instruments used when performing this test.- Serology
- OAntibody assay
- Microsphere Multiplex Flow Immunoassay (MFI)
- xMAP SARS-CoV-2 Multi-Antigen IgG Assay (Luminex Corporation)
Not provided
Clinical validity
HelpHow consistently and accurately the test detects or predicts the intermediate or final outcomes of interest. Lab-provided.Not provided
Comments about the test interpretation (e.g. clinical implication of test results)
Negative: No IgG antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detected. Negative results may occur if the test is done too soon following infection, in patients who are immunosuppressed, or in patients with very mild or asymptomatic infection. This test does not rule out active or recent coronavirus disease 2019 (COVID-19) and will not detect SARS-CoV-2 vaccine-induced antibodies. Positive: Results suggest infection with SARS-CoV-2 at some time in the past. A positive result does not indicate protection against reinfection with SARS-CoV-2. False-positive results may occur. Confirmatory testing using a venipuncture blood draw may be considered in low-risk individuals or those residing in low-prevalence regions. Inconclusive: Presence or absence of antibodies to SARS-CoV-2 could not be determined. Repeat testing on a new dried blood spot specimen or a venipuncture blood draw may be considered.IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.